Share of Pfizer Inc. PFE, -1.95% tumbled 6.5% in premarket trading Monday, enough to pace all of the Dow Jones Industrial Average' DJIA, -0.68% s early decliners after the drug maker said it halted a study of a potential breast-cancer treatment.